A carregar...
BCR-ABL1 kinase: hunting an elusive target with new weapons
Tyrosine kinase inhibitors such as imatinib, dasatinib and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. Recent report in Cell (Grebien et al., 2011) paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228864/ https://ncbi.nlm.nih.gov/pubmed/22118668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chembiol.2011.11.001 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|